Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Naive Crohn ’s Disease

Comparative effectiveness have become increasingly important to help position therapies for inflammatory bowel disease. We compared the efficacy and rapidity of onset of action of infliximab vs. ustekinumab induction therapy for moderate to severe biologic-na ïve Crohn’s disease (CD) using patient-level data from randomized controlled trials.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research